Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer

Gary A Ulaner; Amy M Fowler; Amy S Clark; Hannah Linden

doi:10.1016/j.cpet.2023.04.008

Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer

PET Clin. 2023 Oct;18(4):531-542. doi: 10.1016/j.cpet.2023.04.008. Epub 2023 Jun 1.

Authors

Gary A Ulaner¹, Amy M Fowler², Amy S Clark³, Hannah Linden⁴

Affiliations

¹ Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA; Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA. Electronic address: [email protected].
² Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
³ Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Medical Oncology, University of Washington, Seattle, WA, USA.

PMID: 37270377
DOI: 10.1016/j.cpet.2023.04.008

Abstract

Estrogen receptor (ER)-targeted imaging with 16α-¹⁸F-fluoro-17β-fluoroestradiol (¹⁸F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of ¹⁸F-FES PET for patients with ER-positive breast cancer. Newer progesterone receptor-targeted imaging agents are in clinical trials.

Keywords: Breast cancer; Estrogen receptor; Position emission tomography; Progesterone receptor.

Publication types

Review

MeSH terms

Breast Neoplasms* / drug therapy
Estradiol
Female
Humans
Positron-Emission Tomography
Receptors, Estrogen
Receptors, Progesterone
United States

Substances

Receptors, Estrogen
Estradiol
Receptors, Progesterone